X
X
Total 393357 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| DN1p neuron | Posteriorly located member of the Period-expressing DN1 cluster that expresses glass (FBgn0004618). There are 14-17 DN1p cells per cluster. Many, perhaps all cells in this cluster project through the dorsal fusion commissure (Helfrich-Forster et al., 2007). | ILX:0103360 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| DN2 neuron | DN (dorsal Period-expressing neuron of adult brain) whose medium-sized cell body is located posteriorly in the dorsal superior brain, ventral to the projections of the `s-LNv Pdf neurons` (FBbt_00003764). There are 2 cells in each DN2 cluster. | ILX:0103361 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| DN3 neuron | DN (dorsal Period-expressing neuron of adult brain) with a cell body located in the lateral-most cluster of Period expressing DN neurons. There are around 40 cells in each cluster. | ILX:0103362 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| DN3a neuron | DN (dorsal Period-expressing neuron of adult brain) with a medium-sized cell body, located in the lateral-most cluster of per expressing DN neurons. There are two cells per hemisphere, each of which project anteriorly to the aMe (Helfrich-Forster et al., 2007). | ILX:0103363 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| DNA | Alphabet for a DNA sequence with possible ambiguity, unknown positions and non-sequence characters. | ILX:0103364 | 6 | scicrunch | 06/11/2021 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| DNA methylation | The covalent transfer of a methyl group to either N-6 of adenine or C-5 or N-4 of cytosine (Gene Ontology) | ILX:0103365 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| DNA microarray | A DNA-microarray is a microarray that is used as a physical 2D immobilization matrix for DNA sequences. DNA microarray-bound DNA fragments are used as targets for a hybridizing probed sample. | ILX:0103366 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| DNA specific probe | ILX:0103367 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| DNQX | competitive AMPA/kainate receptor antagonist. | ILX:0103368 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Do Not Exist | no def needed | ILX:0103369 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dobutamine | A beta-2 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery. (PubChem) Pharmacology: Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-adrenoceptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. Dobutamine acts primarily on beta-1 adrenergic receptors, with little effect on beta-2 or alpha receptors. It does not cause the release of endogenous norepinephrine, as does dopamine. Dobutamine is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. Mechanism of action: Dobutamine directly stimulates beta-1 receptors of the heart to increase myocardial contractility and stroke volume, resulting in increased cardiac output. Drug type: Approved. Small Molecule. Drug category: Adrenergic beta-Agonists. Cardiotonic Agents. Sympathomimetic. Sympathomimetics | ILX:0103370 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Docked Vesicle | Synaptic vesicle docked at the pre-synaptic active zone. | ILX:0103372 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Docosanol | Docosanol is a drug used for topical treatment for recurrent herpes simplex labialis episodes (episodes of cold sores or fever blisters). A saturated 22-carbon aliphatic alcohol, docosanol exhibits antiviral activity against many lipid enveloped viruses including herpes simplex virus (HSV). Docosanol inhibits fusion between the plasma membrane and the herpes simplex virus (HSV) envelope, thereby preventing viral entry into cells and subsequent viral replication. Pharmacology: Docosanol is a saturated 22-carbon aliphatic alcohol which exhibits antiviral activity against many lipid enveloped viruses including herpes simplex virus (HSV). Docosanol speeds the healing of cold sores and fever blisters on the face or lips. It also relieves the accompanying symptoms, including tingling, pain, burning, and itching. Docosanol cannot, however, prevent cold sores or fever blisters from appearing. Mechanism of action: Docosanol works by inhibiting fusion between the human cell plasma membrane and the herpes simplex virus (HSV) envelope, thereby preventing viral entry into cells and subsequent viral replication. Unlike other cold-sore antivirals, docosanol does not act directly on the virus, and as such it is unlikely it will produce drug resistant mutants of HSV. Drug type: Approved. Investigational. Small Molecule. Drug category: Antiviral Agents. Dermatologicals | ILX:0103373 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Document | A collection of information content entities intended to be understood together as a whole | ILX:0103374 | 4 | scicrunch | 06/12/2021 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Documentation generation software | A resource that provides a programming tool that generates documentation intended for programmers (API documentation) or end users (End-user Guide), or both, from a set of specially commented source code files, and in some cases, binary files. | ILX:0103375 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dofetilide | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. (Wikipedia) Pharmacology: Dofetilide is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties and is indicated for the maintenance of normal sinus rhythm. Dofetilide increases the monophasic action potential duration in a predictable, concentration-dependent manner, primarily due to delayed repolarization. At concentrations covering several orders of magnitude, Dofetilide blocks only IKr with no relevant block of the other repolarizing potassium currents (e.g., IKs, IK1). At clinically relevant concentrations, Dofetilide has no effect on sodium channels (associated with Class I effect), adrenergic alpha-receptors, or adrenergic beta-receptors. Mechanism of action: The mechanism of action of Dofetilide is a blockade of the cardiac ion channel carrying the rapid component of the delayed rectifier potassium current, IKr. This inhibition of potassium channels results in a prolongation of action potential duration and the effective refractory period of accessory pathways (both anterograde and retrograde conduction in the accessory pathway). Drug type: Approved. Small Molecule. Drug category: Anti-Arrhythmia Agents. Antiarrhythmic Agents. Potassium Channel Blockers | ILX:0103376 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dog | A mammal of the carnivora order and genus canis. | ILX:0103377 | 7 | scicrunch | 04/27/2021 | sawg | term | 12/08/2016 | 0 | NeuroLex | Jeffrey Grethe |
| Dolasetron | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist, not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors. Pharmacology: Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist, not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors. Mechanism of action: Dolasetron is a selective serotonin 5-HT3 receptor antagonist. The serotonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine, and that the released serotonin then activates 5-HT3 receptors located on vagal efferents to initiate the vomiting reflex. Therefore Dolasetron works by blocking the reception of serotonin at these 5-HT3 receptors. Drug type: Approved. Small Molecule. Drug category: Antiemetics. Serotonin Antagonists | ILX:0103378 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Domed | A curvature quality inhering in a bearer by virtue of having a shape resembling a dome. | ILX:0103379 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Domperidone | A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms. (PubChem) Pharmacology: Domperidone is a specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms. Mechanism of action: Gastrointestinal emptying (delayed) adjunct; peristaltic stimulant: The gastroprokinetic properties of domperidone are related to its peripheral dopamine receptor blocking properties. Domperidone facilitates gastric emptying and decreases small bowel transit time by increasing esophageal and gastric peristalsis and by lowering esophageal sphincter pressure. Antiemetic: The antiemetic properties of domperidone are related to its dopamine receptor blocking activity at both the chemoreceptor trigger zone and at the gastric level. Drug type: Approved. Small Molecule. Drug category: Antiemetics. Dopamine Antagonists | ILX:0103380 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
About
Base community for the SciCrunch.org infrastructure
Contact Us
X